US OptionsDetailed Quotes
TSLA241213C385000
- 51.10
- +17.43+51.77%
15min DelayClose Dec 13 16:00 ET
51.10High32.75Low
35.12Open33.67Pre Close925 Volume6.36K Open Interest385.00Strike Price4.04MTurnover0.00%IV-0.03%PremiumDec 13, 2024Expiry Date51.23Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.52Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Tesla Stock Discussion
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
1
6
$Bitcoin (BTC.CC)$ shit!!! I don't know the accuracy of this but brigadanews.ph/... it's definitely a black swan event coming . I really hope this is not real
$NVIDIA (NVDA.US)$ $Microsoft (MSFT.US)$ $Tesla (TSLA.US)$
$NVIDIA (NVDA.US)$ $Microsoft (MSFT.US)$ $Tesla (TSLA.US)$
3
$Tesla (TSLA.US)$
1) Someone shared an article titled "16 top companies in the vanguard of the rise of humanoid robots" and commented that Boston Dynamics' humanoid robot is far ahead of other models. Read here:
16 top companies in the vanguard of the rise of humanoid robots – Ross Dawson
2) If you checked, the article didn't rank the humanoid robot nor commented which one is more superior over the other. It ...
1) Someone shared an article titled "16 top companies in the vanguard of the rise of humanoid robots" and commented that Boston Dynamics' humanoid robot is far ahead of other models. Read here:
16 top companies in the vanguard of the rise of humanoid robots – Ross Dawson
2) If you checked, the article didn't rank the humanoid robot nor commented which one is more superior over the other. It ...
As the year comes to a close, it’s time to reflect on the lessons learned, celebrate successes, and set new goals for the year ahead. This year, my investment journey has been shaped by many insights from my wins & losses, and I want to incorporate Warren Buffett’s timeless advice as a guiding framework for 2025. Here are some key takeaways and how they’ll influence my approach moving forward:
Join Our Year-End Fireside Chat: Mooers Assemble!
📅 Event Date: De...
Join Our Year-End Fireside Chat: Mooers Assemble!
📅 Event Date: De...
+1
1
In my previous post, I showed my 2024 P/L – seemed all roses right? Wrong, it’s actually been a mega roller coaster. I’ve been actively investing for over 3 years, starting with a small capital with the occasional DCA. Since I started when the markets were going down in 2022, I am usually more pessimistic in nature. But this year truly took the cake in testing my conviction, both in myself and the companies I bought shares in.
Startin...
Startin...
29
8
2
No comment yet
Millaai : Are you being trapped and looking for a rescuer everywhere?
Growth Investor27 : Good info, NEXLIZET is a great drug, my brother takes it. ESPR stock is undervalued, should be above $5
Growth Investor27 Millaai : The author has been buying below $2 so your comment is off. This research article has all the due diligence to see, other than the fact Institutions have been heavly buying this year, fintel shows now 74% owned. ESPR is a good investment.
104248191 : please f o
Detached House Millaai : You are wrong. Though short term looks like the price is consolidating, the weekly chart looks promising! So look at the chart to see if it aligns with the fundamentals before criticising others!
View more comments...